AKT1 and cancer: Thus, suppressing BH3-only protein activity through MEK–ERK and PI3K–AKT signaling pathways may be crucial for cancers driven by constitutively activated oncogenic kinases, such as EGFR [49,50,51], BRAF [52], KRAS [53], and BCR–ABL [54].